Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06566261
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-20
Brief Title:
ABA-101 in Participants with Progressive Multiple Sclerosis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 1 Open-label Single Ascending Dose Study of ABA-101 in Participants with Progressive Multiple Sclerosis
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis
It is the first study of this treatment in humans After safety is demonstrated with a low dose of ABA-101 a higher dose will be evaluated
It is the first study of this treatment in humans After safety is demonstrated with a low dose of ABA-101 a higher dose will be evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None